• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Newsletter Sign Up
Contact
  • Home
  • News
  • News
  • Expedited safety reporting in drug clinical trials – new FAQ issued

Expedited safety reporting in drug clinical trials – new FAQ issued

Expedited safety reporting
Tuesday, 28 March 2023 / Published in News, NMPA Registration in China, Pharmaceuticals & DMF

Expedited safety reporting in drug clinical trials – new FAQ issued

Expedited safety reporting in drug clinical trials is a regulatory requirement in China that mandates the applicant to timely inform the Center for Drug Evaluation (CDE) when a suspected unexpected serious adverse reaction (SUSAR) event has occurred.

As a more up-to-date reference to drug registration applicants and contract research organizations (CROs) in China, the CDE released the frequently asked questions for expedited reporting of safety data during drug clinical trials (Version 2.0) on March 17, 2023, replacing the previous version issued in April 2019. Both versions were drafted by the CDE in accordance with the Chinese standards and procedures for expedited reporting of safety data during drug clinical trials, and the respective ICH guidelines.

There are a total of 35 questions addressed and being answered in the latest FAQ covering 5 major aspects:

  • What should be reported?
  • Reporting time frames
  • How to report
  • Responsible party for expedited reporting, account management and testing related matters
  • Other miscellaneous issues

What should be reported?

Scope of drug products

  • Traditional Chinese medicines
  • Chemical drugs
  • Biological products (including vaccines)

Scope of clinical trials

  • Phase I clinical trials
  • Phase II clinical trials
  • Phase III clinical trials
  • Bioequivalence trials
  • Clinical trials for conditionally approved drugs that need to be completed as required
  • Phase IV clinical trials with special requirements in the marketing authorization approval document

Reporting time frames

The applicant should submit the report to the CDE as soon as possible and no later than 7 calendar days after knowing about the fatal or life-threatening SUSAR event. A follow-up report should also be submitted in every 15 calendar days for any new collected information.

How to report

Currently, there are only two types of methods for individual case safety reporting:

  • Gateway
  • XML file upload

For cases when applicants do not have a pharmacovigilance system in place and unable to use both of the above mentioned methods, applicants can still consider entrusting a third party CRO for reporting. Applicants should keep in mind that the CDE does not accept the submission of CIOMS forms in paper format.

Further information

The FAQ (Version 2.0) further clarifies the SUSAR reporting of combined products and other specific issues.

Read the original CDE announcement (No.17-2023) on the frequently asked questions for expedited reporting of safety data during drug clinical trials (Version 2.0).

Contact Cisema if you would like to learn more about complying with the requirements for pharmaceutical products in China.

GET IN TOUCH

🌐 Send us your enquiry
📚 Request our whitepapers
📣 Sign up for our newsletter

What you can read next

NMPA Develops API Production and Supply Information Collection Platform
NMPA issues Technical Guidelines for Cosmetic Safety Assessment (2021 Edition)
Technical regulation TSG 23 – 2021 for gas cylinder safety and 1st amendment of TSG 21 – 2016 published

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • Submission of safety information for cosmetics ingredients

    Submission of safety information for cosmetics raw materials – Draft guidelines issued

    Submission of safety information for cosmetics ...
  • avoid animal testing in Chinaweb-2023

    How to avoid animal testing in China for cosmetics | Cisema Webinar

    China’s beauty and cosmetic market has be...
  • guidelines for medical devices registration

    Guidelines for medical devices registration in China – New development plans in 2023

    Guidelines for medical devices registration in ...
  • China DMF of API

    China DMF of API, Excipient & Packaging Materials: Market & Regulatory | Cisema Webinar

    “China DMF of API, Excipient & Packag...
  • pre-phase III drug clinical trial meeting guidelines

    Pre-phase III drug clinical trial meeting guidelines released

    Pre-phase III drug clinical trial meeting guide...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP